ReviewMolecules (Basel, Switzerland)2014
The azaindole framework in the design of kinase inhibitors.
Review in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Structure-Activity Relationships of Hemocompatible Cationic 6-Azaindole Pyridinium Salts: Antimicrobial and Anticancer Activity.Molecules (Basel, Switzerland) · 2026Article
- Review
- Article
- Hydrogen Bonding in Chloro- and Hydroxy-7-Azaindoles: Insights from X-Ray, Vibrational Spectroscopy, and DFT Studies.Molecules (Basel, Switzerland) · 2025Article
- Optimization of Physicochemical Properties and ADME for 2,4-Substituted 1Journal of medicinal chemistry · 2025Article
- Design, Synthesis, and Bioactivity Assessment of Modified Vemurafenib Analog.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Novel 4-alkoxy Meriolin Congeners Potently Induce Apoptosis in Leukemia and Lymphoma Cells.Molecules (Basel, Switzerland) · 2024Article
- Design and Synthesis of Potential Multi-Target Antidepressants: Exploration of 1-(4-(7-Azaindole)-3,6-dihydropyridin-1-yl)alkyl-3-(1International journal of molecular sciences · 2024Article
- Nickel binding enables isolation and reactivity of previously inaccessible 7-aza-2,3-indolynes.Science (New York, N.Y.) · 2024Article
- Marine-Derived Bisindoles for Potent Selective Cancer Drug Discovery and Development.Molecules (Basel, Switzerland) · 2024Review
- Unlocking New Prenylation Modes: Azaindoles as a New Substrate Class for Indole Prenyltransferases.ChemCatChem · 2023Article
- Nortopsentins as Leads from Marine Organisms for Anticancer and Anti-Inflammatory Agent Development.Molecules (Basel, Switzerland) · 2023Review
- Oxidatively induced reactivity in Rh(iii)-catalyzed 7-azaindole synthesis: insights into the role of the silver additive.Chemical science · 2022Article
- Deprotometalation-Iodolysis and Direct Iodination of 1-Arylated 7-Azaindoles: Reactivity Studies and Molecule Properties.Molecules (Basel, Switzerland) · 2021Article
- Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration.International journal of molecular sciences · 2021Review
- Design, Radiosynthesis and Preliminary Biological Evaluation in Mice of a Brain-PenetrantInternational journal of molecular sciences · 2021Article
- Structure-Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors.International journal of molecular sciences · 2021Article
- Azaindole therapeutic agents.Bioorganic & medicinal chemistry · 2020Article
- Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming.Nature chemical biology · 2020Article
- Development of PotentJournal of medicinal chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review article illustrates the growing use of azaindole derivatives as kinase inhibitors and their contribution to drug discovery and innovation. The different protein kinases which have served as targets and the known molecules which have emerged from medicinal chemistry and Fragment-Based Drug Discovery (FBDD) programs are presented. The various synthetic routes used to access these compounds and the chemical pathways leading to their synthesis are also discussed. An analysis of their mode of binding based on X-ray crystallography data gives structural insights for the design of more potent and selective inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.